0
0
The Indian Medical Association (IMA) has issued a strong warning against the rampant misuse and mis-prescription of new weight-loss drugs such as Wegovy and Mounjaro, urging that these medications be prescribed only by certified endocrinologists or diabetologists. This warning comes amid growing concerns over health risks from unsupervised use, especially by non-specialist practitioners, as well as the potential long-term complications that remain poorly understood. The IMA is pushing government regulators to enforce stricter prescription controls to safeguard public health.
Key Findings and Developments
Wegovy (semaglutide) and Mounjaro (tirzepatide) are glucagon-like peptide-1 receptor agonists (GLP-1 RAs) originally developed to help treat type 2 diabetes and obesity. These drugs help reduce appetite and control blood sugar, enabling medically supervised weight loss in patients with metabolic conditions.
However, their recent introduction in India has seen a surge of inappropriate use. According to IMA national president Dr. Dilip Bhanushali, many non-specialist practitioners—including cosmetologists, physiotherapists, and even alternative medicine providers like Ayurveda and Homeopathy—are prescribing these drugs haphazardly. This misuse is often driven by cosmetic desires to look thinner for social media or public appearances, rather than medical indications.
Dr. Geoffrey Vaz, a dermatologist in Mumbai, noted the alarming increase in random prescriptions of these drugs without proper medical oversight, amplifying risks for patients who receive little to no guidance or follow-up care.
Expert Commentary
Dr. Mayank Madan, a bariatric surgeon at CK Birla Hospital, Gurugram, described seeing 40–50 new cases monthly of patients self-medicating with these potent drugs without monitoring. Such usage can cause severe gastrointestinal and metabolic complications, including nausea, vomiting, pancreatitis, and gallstones. He stressed that the drugs must be started at low doses and gradually titrated under medical supervision; misuse can result in significant adverse effects and metabolic instability.
Dr. Tarun Mittal, vice-chairperson and robotic bariatric surgeon at Sir Ganga Ram Hospital, New Delhi, emphasized that while these drugs are effective for many, they are not magic pills. For example, they may not work well for patients with extremely high body mass index (BMI >50) and are not substitutes for bariatric surgery when substantial weight loss is needed. Side effects such as gastroparesis and eye-related issues require careful management, highlighting the importance of specialist care. He warned against self-medication, which is reportedly seen in 10–15% of patients visiting obesity or bariatric clinics.
From the pharmaceutical perspective, Eli Lilly India, marketer of Mounjaro, reiterated that tirzepatide should only be used under licensed healthcare professional supervision. The company condemns off-label or unauthorized usage, especially due to risks from counterfeit or illegally distributed medications. Experts agree that unregulated online sales represent a significant danger to patient health.
Context and Background
GLP-1 receptor agonists have revolutionized the treatment of obesity and type 2 diabetes by mimicking gut hormones that regulate glucose and appetite. Both Wegovy and Mounjaro have shown robust clinical trial data demonstrating significant weight loss and improved glycemic control in properly selected patients.
Despite this, these drugs carry risks. They can induce gastrointestinal disturbances, exacerbate pancreatitis, alter electrolytes, and potentially cause other systemic side effects. Long-term safety data remains limited given their recent market introduction. The drugs’ complexity requires careful patient selection, dosing adjustments, and monitoring, ideally by specialists trained in metabolic diseases.
The IMA’s concerns align with international cautionary notes from medical bodies, including NHS England, which also warns against these drugs being used as cosmetic “quick fixes.” Instead, they should be part of a comprehensive obesity or diabetes management plan.
Public Health Implications
The misuse of Wegovy and Mounjaro in India poses several public health challenges:
-
Patient Safety Risk: Incorrect dosing and unmonitored use increase the risk of serious side effects and hospitalizations.
-
Potential for Addiction to Quick Fixes: Social pressures and cosmetic desires may fuel inappropriate drug use without addressing underlying health.
-
Resource Strain: Misuse may cause increased healthcare burden from adverse effects and complications requiring treatment.
-
Regulatory Gaps: Broad prescription eligibility without specialist oversight creates loopholes that allow misuse.
The IMA’s call to restrict prescriptions to endocrinologists and diabetologists aims to ensure drugs are used responsibly, with appropriate patient counseling, screening for contraindications, and long-term follow-up.
Limitations and Counterarguments
While specialist-only prescriptions might enhance safety, there is debate about access. Excluding general practitioners might limit availability to some patients who could benefit from these drugs under careful guidance. Also, not all patients with obesity have easy access to endocrinologists or diabetologists, especially in rural India.
Further research is needed to understand long-term safety and real-world use in diverse populations. Until then, balanced regulation that ensures both safety and accessibility is key.
Practical Takeaways for Readers
-
These drugs are powerful medications meant for medical treatment of obesity and diabetes—not for casual or cosmetic weight loss.
-
Only obtain them through prescriptions from qualified specialists who provide thorough evaluation and follow-up.
-
Avoid self-medication or buying weight-loss drugs from unverified sources or online.
-
Discuss potential side effects and realistic expectations with healthcare providers.
-
Understand that sustainable weight loss involves lifestyle changes alongside any medication.
Medical Disclaimer
This article is for informational purposes only and should not be considered medical advice. Always consult with qualified healthcare professionals before making any health-related decisions or changes to your treatment plan. The information presented here is based on current research and expert opinions, which may evolve as new evidence emerges.
References
